HC Wainwright Reiterates Buy Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $80.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 218.22% from the stock’s previous close.

CLDX has been the topic of several other research reports. Citigroup assumed coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Down 0.9 %

CLDX opened at $25.14 on Thursday. The company’s 50-day moving average price is $26.79 and its 200 day moving average price is $33.36. Celldex Therapeutics has a fifty-two week low of $22.93 and a fifty-two week high of $53.18. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -9.78 and a beta of 1.57.

Insider Activity at Celldex Therapeutics

In other news, CEO Anthony S. Marucci bought 11,500 shares of the business’s stock in a transaction on Monday, November 11th. The stock was purchased at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is currently owned by insiders.

Institutional Trading of Celldex Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV grew its holdings in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 495 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Celldex Therapeutics during the 2nd quarter valued at about $76,000. Los Angeles Capital Management LLC grew its stake in shares of Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 638 shares during the last quarter. Quest Partners LLC raised its holdings in shares of Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 6,879 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Celldex Therapeutics by 23.7% during the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after purchasing an additional 1,504 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.